Funding for this research was provided by:
The work was conducted in the context of a European Commission sponsored joint action, Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE). (ECM-2294., The survey was made possible through a tendered sub contract ITT-1301)
First Online: 2 March 2018
Change Date: 30 June 2020
Change Type: Correction
Change Details: In the original publication of the article, the headings of columns 3 and 4 in the data table.
Compliance with Ethical Standards
: Ethical approval was not considered necessary for this study because of the nature of the study, in which healthcare professionals were asked to complete a survey about safety communication strategies. Participants were assured that all sensitive data would be kept confidential.
: The work was conducted in the context of a European Commission sponsored joint action, Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE). Any opinions, conclusions and proposals in the text are those of the authors and do not necessarily represent the views of the European Commission or national competent authorities. The survey was made possible through a tendered subcontract ITT-1301, ECM-2294.
: Sieta T. de Vries, Maartje J.M. van der Sar, Anna Marie Coleman, Yvette Escudero, Alfonso Rodríguez Pascual, Miguel-Ángel Maciá Martínez, Amelia Cupelli, Ilaria Baldelli, Ivana Šipić, Adriana Andrić, Line Michan, and Petra Denig have no conflicts of interest that are directly relevant to the content of this study. Peter G.M. Mol is an employee of the Dutch Medicines Evaluation Board.